Showing 3003 results
-
Press release /RemIND data show clinically meaningful responses through Week 52 across three most prevalent CIndU subtypes, including after switching from placebo at Week 241Twice as many Rhapsido-treated patients…
-
Press release /Patients continuing ianalumab saw further improvement in systemic disease activity through Week 108, with no new safety findings1 Nearly two-thirds of patients on continuous ianalumab reached low…
-
Event / Oct 27, 2026Novartis announces the company’s financial results for the third quarter of 2026.